These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 30073642)

  • 41. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
    Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
    Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
    Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
    Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
    Chamberlain MC; Grimm S; Phuphanich S; Recht L; Zhu JZ; Kim L; Rosenfeld S; Fadul CE;
    J Neurooncol; 2014 Jun; 118(2):335-343. PubMed ID: 24740196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
    J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
    Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
    Gandara DR; von Pawel J; Mazieres J; Sullivan R; Helland Å; Han JY; Ponce Aix S; Rittmeyer A; Barlesi F; Kubo T; Park K; Goldschmidt J; Gandhi M; Yun C; Yu W; Matheny C; He P; Sandler A; Ballinger M; Fehrenbacher L
    J Thorac Oncol; 2018 Dec; 13(12):1906-1918. PubMed ID: 30217492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
    Urup T; Gillberg L; Kaastrup K; Lü MJS; Michaelsen SR; Andrée Larsen V; Christensen IJ; Broholm H; Lassen U; Grønbaek K; Poulsen HS
    Mol Oncol; 2020 May; 14(5):964-973. PubMed ID: 32133779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
    J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
    Necchi A; Joseph RW; Loriot Y; Hoffman-Censits J; Perez-Gracia JL; Petrylak DP; Derleth CL; Tayama D; Zhu Q; Ding B; Kaiser C; Rosenberg JE
    Ann Oncol; 2017 Dec; 28(12):3044-3050. PubMed ID: 28950298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
    Choi SW; Jung HA; Cho HJ; Kim TM; Park CK; Nam DH; Lee SH
    Cancer Med; 2023 Aug; 12(15):15788-15796. PubMed ID: 37537946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
    Watanabe K; Kanaya H; Fujiyama Y; Kim P
    Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.